tetano
Editor, Senior Moderator
Expert Opin Pharmacother. 2019 Jun 6:1-8. doi: 10.1080/14656566.2019.1626824. [Epub ahead of print]
[h=1]Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.[/h] Bassetti M[SUP]1[/SUP], Castaldo N[SUP]1[/SUP], Carnelutti A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Introduction: Influenza represents a major public health threat worldwide. Implementation of good personal health and hygiene habits, together with vaccination, is the most effective tools to reduce influenza burden both in community and in healthcare setting. However, achieving adequate vaccination rates is challenging, and vaccination does not always guarantee complete protection. Neuraminidase inhibitors represent an important measure to reduce the risk of influenza-related complications among high-risk patients developing influenza infection. Areas covered: Neuraminidase inhibitors have been proven to be safe and effective in reducing influenza severity, duration of symptoms, hospitalizations, and influenza-related-mortality. Here the authors review the available data on neuraminidase inhibitors, including the mechanism of action, pharmacokinetics, efficacy, safety and current indications for their use in clinical practice. Expert opinion: Although vaccination is the most effective tool to reduce influenza-associated morbidity and mortality, neuraminidase inhibitors represent an important option for the treatment of patients with influenza infection, particularly in high-risk categories. Moreover, antivirals play an important role in influenza prevention and prophylaxis in selected settings.
[h=4]KEYWORDS:[/h] Influenza; laninamivir; neuraminidase inhibitor; oseltamivir; peramivir; zanamivir
PMID: 31169040 DOI: 10.1080/14656566.2019.1626824
[h=1]Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.[/h] Bassetti M[SUP]1[/SUP], Castaldo N[SUP]1[/SUP], Carnelutti A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Introduction: Influenza represents a major public health threat worldwide. Implementation of good personal health and hygiene habits, together with vaccination, is the most effective tools to reduce influenza burden both in community and in healthcare setting. However, achieving adequate vaccination rates is challenging, and vaccination does not always guarantee complete protection. Neuraminidase inhibitors represent an important measure to reduce the risk of influenza-related complications among high-risk patients developing influenza infection. Areas covered: Neuraminidase inhibitors have been proven to be safe and effective in reducing influenza severity, duration of symptoms, hospitalizations, and influenza-related-mortality. Here the authors review the available data on neuraminidase inhibitors, including the mechanism of action, pharmacokinetics, efficacy, safety and current indications for their use in clinical practice. Expert opinion: Although vaccination is the most effective tool to reduce influenza-associated morbidity and mortality, neuraminidase inhibitors represent an important option for the treatment of patients with influenza infection, particularly in high-risk categories. Moreover, antivirals play an important role in influenza prevention and prophylaxis in selected settings.
[h=4]KEYWORDS:[/h] Influenza; laninamivir; neuraminidase inhibitor; oseltamivir; peramivir; zanamivir
PMID: 31169040 DOI: 10.1080/14656566.2019.1626824